Geode Capital Management’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,221,125
| Closed | -$4.89M | – | 4521 |
|
|
2025
Q2 | $4.89M | Sell |
1,221,125
-9,640
| -0.8% | -$23.9K | ﹤0.01% | 2744 |
|
|
2025
Q1 | $1.12M | Buy |
1,230,765
+51,143
| +4% | +$70.9K | ﹤0.01% | 3267 |
|
|
2024
Q4 | $3.27M | Buy |
1,179,622
+8,450
| +0.7% | +$32.1K | ﹤0.01% | 2946 |
|
|
2024
Q3 | $6.13M | Buy |
1,171,172
+19,499
| +2% | +$101K | ﹤0.01% | 2656 |
|
|
2024
Q2 | $5.14M | Buy |
1,151,673
+84,194
| +8% | +$408K | ﹤0.01% | 2701 |
|
|
2024
Q1 | $8.18M | Buy |
1,067,479
+34,763
| +3% | +$191K | ﹤0.01% | 2444 |
|
|
2023
Q4 | $4.4M | Buy |
1,032,716
+209,893
| +26% | +$746K | ﹤0.01% | 2769 |
|
|
2023
Q3 | $3.46M | Buy |
822,823
+205,364
| +33% | +$1.04M | ﹤0.01% | 2825 |
|
|
2023
Q2 | $3.44M | Buy |
617,459
+376,251
| +156% | +$2.22M | ﹤0.01% | 2895 |
|
|
2023
Q1 | $1.38M | Buy |
241,208
+8,082
| +3% | +$21.4K | ﹤0.01% | 3202 |
|
|
2022
Q4 | $244K | Sell |
233,126
-559
| -0.2% | -$977 | ﹤0.01% | 3989 |
|
|
2022
Q3 | $626K | Buy |
233,685
+16,760
| +8% | +$60.6K | ﹤0.01% | 3608 |
|
|
2022
Q2 | $1.03M | Buy |
216,925
+30,918
| +17% | +$134K | ﹤0.01% | 3405 |
|
|
2022
Q1 | $760K | Buy |
186,007
+1,988
| +1% | +$11.7K | ﹤0.01% | 3735 |
|
|
2021
Q4 | $1.25M | Sell |
184,019
-14,605
| -7% | -$126K | ﹤0.01% | 3596 |
|
|
2021
Q3 | $2.3M | Buy |
198,624
+18,952
| +11% | +$296K | ﹤0.01% | 3287 |
|
|
2021
Q2 | $3.06M | Buy |
179,672
+29,311
| +19% | +$510K | ﹤0.01% | 3137 |
|
|
2021
Q1 | $2.98M | Buy |
150,361
+43,915
| +41% | +$969K | ﹤0.01% | 3058 |
|
|
2020
Q4 | $2.2M | Buy |
106,446
+8,162
| +8% | +$194K | ﹤0.01% | 3033 |
|
|
2020
Q3 | $2.58M | Buy |
+98,284
| New | +$2.44M | ﹤0.01% | 2742 |
|